Latest Insights - page 13 | BiopharmaTrend

The Emergence of Diffusion Generative Models in Accelerating AI Drug Discovery

Recently, diffusion generative models, such as DALL-E 3, Midjourney or Imagen, have attracted considerable interest for their ability to create captivating and inventive images based on textual prompts. Researchers at …

Continue ›››

Insilico Medicine and Servier Enter up to $888M Oncology R&D Deal

Shortly after raising more than $290 million in its 2025 Hong Kong listing—one of the region’s largest biotech and AI IPOs of the year—Insilico Medicine entered a multi-year oncology R&D …

Continue ›››

Insilico Medicine Raises More Than US$290 Million in Hong Kong’s Largest Biotech IPO of 2025

AI-driven drug discovery company Insilico Medicine raised approximately HKD 2.28 billion (more than US$290 million) in its initial public offering on the Hong Kong Stock Exchange today, marking the largest …

Continue ›››

Novo Nordisk Scores Major Win as Oral Weight-Loss Pill Gets FDA Nod — and the Race for Obesity Drugs Just Got Hotter

In what feels like the moment biotech meets everyday life, the U.S. Food and Drug Administration has just approved the first daily oral weight-loss pill containing semaglutide, the same GLP-1 molecule …

Continue ›››

Insilico Medicine Goes for Hong Kong IPO, Aims to Raise $292M

AI drug developer Insilico Medicine has returned to the Hong Kong public markets with an updated IPO prospectus, targeting about $292 million in proceeds. The submission marks the company’s fourth bid …

Continue ›››

Bioptimus Releases Multimodal "World Model" For Biology Covering Histology, Transcriptomics, And Clinical Data

Bioptimus has announced M-Optimus, a foundation model trained on multimodal biomedical data including histology, bulk and spatial transcriptomics, and clinical records, aiming to simulate biological processes across cells, tissues, and …

Continue ›››

Beyond Traditional Medicine: Exploring the Revolutionary Therapies Transforming Patient Care

Biotechnology has revolutionized the healthcare industry, and with the increasing demand for advanced therapies, the focus has shifted towards innovative therapeutic modalities. In this blog article, we will explore some …

Continue ›››

Latent Labs Announces AI-Generated Antibodies with Low Immune Activation

Latent Labs, which emerged from stealth earlier this year with $50 million in funding, has announced Latent-X2, a generative AI model that produces antibody and peptide drug candidates with preclinical-like …

Continue ›››

OpenAI-Backed Chai Discovery Raises $130M at $1.3B Valuation to Scale AI-Driven Antibody Design

OpenAI-backed Chai Discovery, founded in 2024, has raised $130M in a Series B round, valuing the company at $1.3B and bringing total funding to $225M just four months after its …

Continue ›››

10 Companies Shaping the Brain-Computer Interface Landscape: Invasive vs Non-Invasive BCI Technology

The brain–computer interface (BCI) technology domain is constantly progressing as researchers and companies collaborate to devise inventive solutions that connect the human brain with external devices. This expanding sector, driven …

Continue ›››

Aging, AI, and the Uneven Road to Longevity Medicine

Echoing notes from ARDD2025, we briefly overview geroscience, its fusion with AI, what companies pursue in this field and limitations on the way of longevity medicine. А couple of weeks …

Continue ›››